Orthocell Non-Executive Chairman and Director John Van Der Wielen talked with Proactive about the company’s record-breaking quarterly results, achieving revenue of 3.00 million dollars for the first time. Van Der Wielen said, “It’s the sixth quarter in a row that we’ve displayed growth, and for investors, we’re very confident that will continue.”
The result was driven primarily by Orthocell’s activities in Australia, New Zealand, and Singapore, which accounted for more than 90% of quarterly revenue. Importantly, Orthocell has now started commercial progress in new international markets. In the United States, where regulatory approval was only granted in April, the company has lodged 53 hospital applications, secured 14 approvals, and generated its first revenues. Van Der Wielen highlighted that this marks the beginning of operations in the U.S., with expectations of strong future growth.
Canada is also on track, with the appointment of a distributor and upcoming first sales expected in the current quarter. Training programs are underway at a major medical conference, with surgeons being introduced to Orthocell’s Remplir device. Additionally, the company has secured approvals in Thailand and Hong Kong, pointing to a broader international rollout in the coming months.
With six consecutive quarters of growth and new markets set to contribute, Orthocell believes the fundamentals are in place for continued expansion.
For more videos from Proactive, don’t forget to give this video a like, subscribe to our channel, and turn on notifications for future updates.
#MedicalDevices #HealthcareInnovation #QuarterlyResults #USMarket #CanadaExpansion #SurgicalDevices